The use of hypomethylating agents in hematologic malignancies: treatment preferences and results.

Published in: International journal of hematologic oncology (2021)

The advantage in terms of response for MDS and no survival difference between AZA and DAC for AML and MDS patients will be an important contribution to the literature.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
systematic review
newly diagnosed
acute myeloid leukemia
peritoneal dialysis
prognostic factors
acute lymphoblastic leukemia